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Context: A polymorphism of the GH receptor (GHR) gene resulting in genomic deletion of exon 3
(GHR-d3) has been associated with responsiveness to GH therapy. However, the data reported so
far do vary according to the underlying condition, replacement dose, and duration of the
treatment.
Objective, Design: The aim of this study was to analyze the impact of the GHR genotypes in terms
of the initial height velocity (HV) resulting from treatment and the impact upon adult height in
patients suffering from severe isolated GH deficiency.
Controls, Patients, Setting: A total of 181 subjects (peak stimulated GH  2 ng/ml) were studied.
In addition, GHR genotype frequency was compared with a healthy adult control group.
Interventions: Based on the various GHR genotypes, HV, effect of recombinant human GH dose
used, and final height were analyzed.
MainOutcomeMeasures, Results: In the 181 subjects after the first two yr on recombinant human
GH treatment, HV SD score (SDS) as well as height gain were significantly greater in subjects with
the GHR-d3/d3 genotype when compared with the subjects presenting with the GHR-full-length/
full-lengthgenotype (P 0.05). AGHR-d3 allele dose-dependent effectwas found for bothHVSDS
(r  0.72) and height gain (r  0.77). However, there was no significant difference in final adult
height and height SDS according to the exon-3 genotypes.
Conclusions:Our results indicate that in patients with severe isolated GH deficiency, although the
GHRgenotypemight play a role inGH responsiveness, at least at thebeginningof treatment, there
is no effect on final height. (J Clin Endocrinol Metab 93: 974–980, 2008)
GH deficiency (GHD) is heterogeneous in terms of etiology,pathogenesis, and age at diagnosis. Improvement in adult
height is the major aim of treating GH-deficient children with
recombinant humanGH (rhGH) (1). The final height attained as
a result of intervention is influenced, in part, by the dose, injec-
tion frequency, and duration of rhGH therapy. Despite optimi-
zation of these factors, a proportion of GH-deficient patients do
not reach their target height (1, 2). A number of mathematical
models for predicting growth and final outcome has been pro-
posed, enabling the clinician to “personalize” the growth pro-
moting therapy on the grounds of efficacy and economy (2–8).
However, a range of responsiveness to rhGH exists, even when
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factors such as statural deficit before treatment, bone “age,”
midparental height, injection frequency, and dose of rhGH are
considered.
It is likely that underlying genetic and epigenetic factors may
explain this individual variability of GH response. Based on an-
imal knockout and human mutational analysis, the most likely
candidates are factors/genes affecting IGFgeneration (9).Apoly-
morphism in the GH receptor (GHR) gene leading to retention
[full-length (fl)] or deletion of exon 3 (d3), which encodes a
22-amino acid residue sequence in the extracellular domain (10,
11), has recently been associated with the degree of height in-
crease in response to GH replacement in children born short for
gestational age (SGA), those with idiopathic short stature (ISS)
(12), and in aGH-deficient population (13). Patientswith at least
oned3allele hada significantlybetter first-year response, leading
to an improved adult height onGH treatment than patients with
homozygosity for GHR-fl (13). However, reported studies are
not all consistent, which may reflect differing populations and
conditions (14–19). This makes the application of a pharmaco-
genetics/genomic approach to therapy problematic.
The aimof this studywas to evaluate the impact of the exon-3
GHR genotype on short-term growth response and final height
in severely GH-deficient children treated with rhGH. We now
report the results of the short-term growth response of 181 se-
verely GH-deficient children treated for 4 yr (study A) according
to the exon-3 GHR genotype and, in addition, the results of the
long-term growth response of 95 severely GH-deficient children
treated to final height (study B).
Subjects and Methods
Subjects
Study A: follow-up of 4 yr [median rhGH; 31.5 g/kgd
(range 24–38); 20 IU/m2wk (range 15–24)]
A total of 181 subjects with severe growth retardation due to isolated
GHD(IGHD)was studied.Auxological data are shown inTable 1.These
subjects belonged to 124 nonconsanguineous, unrelated families of Cau-
casian origin. Diagnostic criteria included a pretreatment height of less
than3.0 SD score (SDS), decreased height velocity (HV) (2.5 SDS),
retarded bone age (BA), normal karyotype, normal prolactin concentra-
tion and thyroid function, andpeakGHconcentrations less thanor equal
to 2 ng/ml after two stimulation tests (20–23). The remainder of the
hypothalamic-pituitary axis tested normal (23). Standard auxological
assessment was performed (21, 22). None of the affected patients had
evidence of an organic disease, psychosocial deprivation, or any eating
disorder, and all had normal renal and hepatic function. The BA was
estimated according to themethodsofGreulich andPyle (24) andTanner
et al. (25).No other hormonal deficiency occurred over the study period.
Informed consent was obtained from parents and all family members
studied. The study was approved by the Clinical Research Ethics
Committee.
Study B: up to final height [median rhGH; 27.0 g/kgd
(range 24–31); 17.0 IU/m2wk (range 15–19.5)]
From study A, we identified a subgroup of 95 subjects with severe
growth retardation secondary to IGHD, and who had reached final
height. Auxological data are shown in Table 2. These subjects belonged
to 63 nonconsanguineous, unrelated families of Caucasian origin. Di-
agnostic criteria and stimulation tests are described previously.No other
hormonal deficiency occurred over the study period. Informed consent
was obtained from parents and all family members studied. The study
was approved by the Clinical Research Ethics Committee.
Adult control population
A control population composed of 144 healthy adult males recruited
at the medical checkup before military service in Switzerland (age range
19–22 yr), and of 67 healthywomen recruited at the UniversityHospital
in Bern, Switzerland (age range 20–50 yr), was studied. All control sub-
jects were of normal height ( 2 and  2 SDS) (20). None of the
subjects had a family history of pathological short stature, or had re-
ceived any therapy with rhGH or any other anabolic agent. The study
was approved by the Clinical Research Ethics Committee.
Hormonal assays
Pituitary stimulation tests were performed as described previously
(23, 26). Over the years, GH, IGF-I, TSH, LH, FSH, and prolactin were
measured using various assays, as previously described. The correlations
among the different tests were between r  0.83 and 0.97.
GH assays
GH was measured using an immunoradiometric assay, HGH
MAIAclone (Biodata Diagnostics, Freiburg, Germany), which incorpo-
rates two high-affinity monoclonal antibodies. The interassay coeffi-
cients of variation were 2.3, 2.4, and 2.2% at 2, 9, and 24 ng/ml,
respectively. The intraassay coefficients of variation were 2, 1.7, and
1.7% at 2, 9, and 24 ng/ml.
TABLE 1. Auxological data and characteristics of subjects studied at commencement of rhGH replacement therapy median
(range) rhGH dose: 31.5 (24–38) g/kgd
Characteristics
Males (n  98) Females (n  83)
fl/fl
50 (51.0%)
fl/d3
37 (37.8%)
d3/d3
11 (11.2%)
fl/fl
40 (48.2%)
fl/d3
33 (39.7%)
d3/d3
10 (12.1%)
CA (yr) 6.7  2.2 6.2  1.8 6.5  1.6 6.7  2.1 6.8  2.0 5.9  1.6
CA  BA (yr) 3.3  1.3 3.2  1.3 3.3  1.8 3.4  1.4 3.0  1.2 3.0  2.0
Ht SDS 4.1  0.6 4.0  0.5 3.8  0.5 4.2  0.7 3.9  0.3 3.9  0.4
Midparental target Ht (cm) 175.2  4.7 174.8  4.0 175.1  4.1 163.6  4.7 163.0  3.9 162.7  3.8
Midparental target Ht (SDS) 0.2  0.8 0.3  0.7 0.2  0.7 0.3  0.8 0.4  0.7 0.4  0.6
Peak GH (ng/ml) 0.8  0.4 0.7  0.3 0.9  0.4 0.8  0.4 1.1  0.5 0.7  0.3
IGF-I SDS 3.3  1.2 3.4  1.7 3.8  1.4 3.4  1.5 3.6  1.6 3.7  1.4
TW-2 predicted adult Ht (cm) 156.9  7.5 156.3  8.0 157.4  7.6 141.8  7.3 144.1  6.6 142.5  7.0
TW-2 predicted adult Ht (SDS) 3.8  1.5 3.9  1.8 3.7  1.5 3.6  1.1 3.2  0.9 3.4  1.3
CA, Chronological age; Ht, height.
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IGF-I assays
IGF-I concentrations were determined by either IGF-I kit (Nichols
InstituteDiagnostics, BadVilbel,Germany) or using the assays described
by Blum et al. (27).
DNA isolation and GH-1/GHR gene analysis
Genomic DNA was isolated from peripheral leukocytes of subjects
and their relatives (28). The entire GH-1 gene was sequenced as previ-
ously described (29, 30). For genotyping of the GHR exon-3 locus, a
simple multiplex PCR assay was used as previously described (10). Am-
plification products were analyzed by electrophoresis on a 1% agarose
gel stainedwith ethidiumbromide.GHR-fl allelewas detected as a single
band corresponding to 935 bp and the GHR-d3 allele corresponding to
532 bp, respectively.
Statistical analysis
Qualitative variables are listed in row numbers, frequencies, as well
as in percentages. However, quantitative variables are stated in mean
values  SD. Hardy-Weinberg equilibrium was calculated according to
standard procedures using 2 analysis. Differences for GHR-d3/fl geno-
type frequencies between isolated GH-deficient subjects, controls, and
height SDS groups were analyzed by the 2 test. In addition, differences
between GHR-d3/fl genotypes for auxological parameters in GH-defi-
cient subjects were assessed using ANOVA Fisher’s protected least sig-
nificant difference test. P values less than 0.05 were considered signifi-
cant. Furthermore, a multiple linear regression analysis assessing the
established influential factors influencing its prognostic significance was
performed. All statistical analyses were performed using SigmaStat for
Windows (version 3.5; Systat Software UK Ltd., London, UK).
Results
Population studies and GHR-genotype frequencies
To compare the affected families with a normal population,
theGHRgenotypes in 211 unrelated normal Swiss subjects were
analyzed (20). Individual allele frequencies of controls and par-
ents of isolated GH-deficient subjects were similar in the three
height subgroups, and genotype frequencies reached Hardy-
Weinberg equilibrium in all the height subgroups studied. Im-
portantly, the genotype frequency of the isolated GH-deficient
subjects, as well as the overall control group, was similar, as it
was when the genotype frequencies were compared with the
overall parental data (Table 3).
Study A
All patients showed severe IGHD, and sequencing of the en-
tireGH-1 gene did not reveal any abnormalities. Stimulated GH
peaks ranged between 0.3 and 2.0 ng/ml. At the commencement
of rhGH replacement therapy, the age of the patients ranged
between4.6and9.5yr.TheBAdelay rangedbetween0.8and5.1
yr. Chronological age, BA delay, height SDS, midparental target
height SDS, and Tanner-Whitehouse-2 prediction (TW-2) adult
height SDSwere not statistically different between boys and girls
or between GHR genotypes (Table 1).
The first-year HV SDS was significantly higher in subjects
with theGHR-d3/d3 genotypewhen comparedwith the subjects
with the GHR-fl/fl genotype (P  0.05) (Table 4). Although,
overall, patients carrying the GHR-d3/fl genotype when com-
paredwithGHR-fl/fl did not presentwith a statistically different
HVSDS (P0.07), a significantly higherHVSDSwas, however,
observed in patients with one or two copies of GHR-d3 when
compared with subjects homozygous for GHR-fl/fl (P  0.05);
therefore, a GHR-d3 allele dose-dependent effect on HV SDS
was found (r 0.72). In addition, comparedwith GHR-fl/fl, the
height gain after 2-yr treatment expressed in SDS was signifi-
cantlyhigher inbothgirls andboys carrying theGHR-d3/d3 (P
0.05) (Table4). Furthermore, theGHR-d3allele dose-dependent
TABLE 2. Auxological data and characteristics of subjects studied at commencement of rhGH replacement therapy (final height
study, mean  SD rhGH dose: 26.5  1.3 g/kgd)
Characteristics
Males (n  52) Females (n  43)
fl/fl
27 (51.9%)
fl/d3
19 (36.5%)
d3/d3
6 (11.6%)
fl/fl
21 (48.8%)
fl/d3
17 (39.5%)
d3/d3
5 (11.7%)
Beginning rhGH therapy
CA (yr) 7.3  2.1 7.0  1.7 7.2  1.4 7.2  2.0 7.3  1.9 6.0  1.3
CA  BA (yr) 3.4  1.3 3.2  1.2 3.3  1.8 3.6  1.2 3.3  1.1 3.0  2.0
Ht SDS 4.2  0.5 3.9  0.5 3.8  0.3 4.3  0.6 3.9  0.3 3.9  0.4
Midparental target Ht (cm) 176.6  5.0 175.3  4.2 177.2  4.0 164.2  4.6 162.9  4.1 163.2  3.5
Midparental target Ht (SDS) 0.2  0.8 0.3  0.6 0.2  0.7 0.2  0.8 0.4  0.6 0.3  0.6
Peak GH (ng/ml) 0.4  0.3 0.4  0.2 0.5  0.3 0.3  0.2 0.6  0.3 0.5  0.3
IGF-I SDS 3.4  1.2 3.3  1.8 4.1  1.2 3.5  1.5 3.8  1.3 3.8  1.6
TW-2 predicted adult Ht (cm) 157.8  8.0 158.1  7.9 158.2  7.5 142.2  7.4 145.5  6.5 143.4  7.1
TW-2 predicted adult Ht (SDS) 3.8  1.6 3.6  1.4 3.6  1.5 3.4  1.1 3.0  0.7 3.4  1.3
End rhGH therapy
Duration of rhGH treatment (yr) 11.6  1.8 11.3  2.0 10.7  1.6 11.0  1.8 11.1  2.2 10.9  1.6
Adult Ht (cm) 173.9  6.7 172.9  7.4 174.1  6.5 161.6  6.9 161.1  4.5 160.3  3.8
Adult Ht (SDS) 0.4  1.0 0.6  1.2 0.3  0.9 0.6  1.3 0.6  1.2 0.7  0.7
Adult Ht SDS  midparental target Ht SDS 0.6  0.7 0.3  1.0 0.5  1.1 0.4  1.2 0.2  1.1 0.4  0.9
Age at onset of puberty (yr)a 13.0  3.2 12.3  2.8 11.6  2.3 11.5  2.0 10.7  2.2 10.4  1.9
Change in Ht SDS on therapy 3.6  0.9 3.3  0.8 3.4  0.6 3.7  1.2 3.3  1.0 3.2  0.4
Adult Ht  PAH at start of treatment (cm) 16.1  7.2 18.7  6.5 17.3  7.2 19.8  6.7 18.1  7.1 18.8  6.9
CA, Chronological age; Ht, height; PAH, predicted adult height.
a Boys, testicle size more than or equal to 4 ml; girls, breast stage Tanner II.
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effect was also present (r 0.77). Although the growth response
during the first 2 yr was better in subjects expressing either the
GHR-d3/d3 or the GHR-d3/fl genotype, during the third (P 
0.05:males and females) and fourth (P0.05: females;P0.07:
males) year on treatment, the opposite was noted. Finally, sub-
jects with the GHR-d3/d3 genotype showed a trend toward an
earlier start of pubertal development.However, this observation
was not statistically significant.
Study B
Of the 181 subjects analyzed in study A, 95 reached final
height andhavebeen separately analyzed (Table2).Therewasno
significant difference in adult height and adult height SDS ac-
cording to the exon-3 genotypes. All subjects independently of
their genotype showed slightly lower adult height SDS compared
with midparental height SDS (Table 2).
Therefore, the effect of rhGH replacement therapy at a me-
dian dose of 27.0 g/kgd did not reveal any difference between
the various genotypes in terms of final height.
Multiple linear regression model
Weperformedmultiple linear regression analysis considering
the genotype, chronological age, height SDS at start of replace-
ment therapy, BA, durationof treatment, age at puberty, andGH
dose. GHR genotype showed a significant relationship (P 
0.05) with growth during the first years of replacement therapy,
which, however, was not demonstrated at final height (Tables 2
and 4). Furthermore, study B (final height study) did not reveal
any variables significantly related to HV.
To study the impact of rhGHdose on growth in subjects with
IGHD carrying different GHR isoforms, the study population
was divided into two groups: group A (n 95), 52males and 43
females, rhGH dose 26.5 1.3 (mean SD) g/kgd; and group
B (n  86), 46 males and 40 females, rhGH dose 36.5  2.1
g/kgd). Importantly, these two groups, although identical in
terms of clinical as well as laboratory findings, do not overlap in
terms of rhGH dose used, and, therefore, this separate analysis
is statistically valid. A relationship between HV SDS in the first-
year treatment and GHR genotype (homo- and heterozygosity
TABLE 4. Auxological parameters on rhGH treatment median (range) rhGH dose: 31.5 (24–38) g/kgd
Characteristics
Males (n  98) Females (n  83)
fl/fl
50
(51.0%)
fl/d3
37
(37.8%)
d3/d3
11
(11.2%)
fl/fl
40
(48.2%)
fl/d3
33
(39.7%)
d3/d3
10
(12.1%)
First-year HV-SDS median rhGH: 30.8 g/kgd 5.5  1.5 6.0  1.7 6.3  1.8a 5.5  1.7 5.7  2.1 6.1  1.6b
Second-year HV-SDS median rhGH: 31.3 g/kgd 3.9  1.9 4.1  1.6 4.1  1.8 3.6  1.7 3.9  1.8 3.9  1.4
Ht gain (first  second year; SDS) 2.3  0.7 2.4  0.8 2.6  1.0a 2.1  0.8 2.4  0.7 2.5  0.4a
Third-year HV-SDS median rhGH: 31.9 g/kgd 2.0  0.7c 1.8  0.8 1.6  0.9 2.0  0.5c 1.8  0.6 1.5  0.7
Fourth-year HV-SDS median rhGH: 31.4 g/kgd 1.8  0.6 1.6  0.5 1.5  0.7 1.7  0.8c 1.3  0.7 1.2  0.6
Ht gain (third to fourth year; SDS) 0.7  0.4 0.6  0.4 0.6  0.3 0.8  0.5 0.6  0.4 0.5  0.3
Ht, Height.
a P  0.05 (d3/d3 vs. fl/fl).
b P  0.01 (d3/d3 vs. fl/fl).
c P  0.05 (fl/fl vs. d3/d3).
TABLE 3. Genotype frequency among IGHD subjects and their the parents (2  117  234), and among the adult control
population
Height SDS
<2 and >1 <1 and > 1 < 1 and > 2 <2 and > 2
IGHD parents IGHD subjects
No. of subjects 50 136 62 248 181
Frequency d3/d3 (n) 22.0% (11) 16.9% (23) 14.5% (9) 17.3% (43) 11.6% (21)
Frequency d3/fl (n) 48.1% (24) 47.8% (65) 48.4% (30) 48.0% (119) 38.7% (70)
Frequency fl/fl (n) 29.9% (15) 35.3% (48) 37.1% (23) 34.7% (86) 49.7% (90)
d3 allele frequency 0.43 0.38 0.35 0.39 0.32
fl allele frequency 0.57 0.62 0.65 0.61 0.68
Adult control population
No. of subjects (m/f) 38 (30/8) 148 (97/51) 25 (17/8) 211 (144/67)
Frequency d3/d3 (n) 13.1% (5) 7.4% (11) 8.0% (2) 8.5% (18)
Frequency d3/fl (n) 47.4% (18) 42.6% (63) 44.0% (11) 43.6% (92)
Frequency fl/fl (n) 39.5% (15) 50.0% (74) 48.0% (12) 47.9% (101)
d3 allele frequency 0.37 0.29 0.30 0.30
fl allele frequency 0.63 0.71 0.70 0.70
f, Female; m, male.
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forGHR-d3) (P0.01)wasdemonstrated in groupA.TheGHR
genotype explained 22% of the variability in HV SDS as well as
height gain during the first-year rhGH treatment. Importantly,
this relationship could not be found in subjects with the higher
rhGH treatment dose (group B). The clinical details are submit-
ted as supplemental files, which are published as supplemental
data on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org.
Discussion
In this study we analyzed the impact of GHR genotypes (GHR-
d3/d3, GHR-d3/fl, and GHR-fl/fl) on growth response to rhGH
replacement therapy in patients suffering from severe IGHD
(meanmaximal GH peak onGH stimulation tests: 0.9 ng/ml). A
total of181childrenwere followed (studyA;Tables1and4), and
prepubertal HVs during the first 4 yr on rhGH replacement (me-
dian dose 31.5 g/kgd) were assessed. In contrast to previous
studies, in our study the subjectswith theGHR-d3/d3 andGHR-
d3/fl were not only pooled but also separately analyzed (13, 18).
Importantly, in the subjects presenting with either GHR-d3/d3
or pooled, so that they had at least one copy of the GHR-d3, an
overall significantly better response to the replacement therapy
during the first 2-yr therapywas noted, although in the third and
fourth year of therapy, this improved HVwas observed in those
patientswith theGHR-fl/fl genotype. In addition, during the first
2 yr on therapy, a GHR-d3 allele-dependent effect on height was
found in study A (r 0.72). However, at final height (study B),
the effect of rhGH treatment was identical regardless of the spe-
cific GHR genotype. It is worth stressing that the difference be-
tween final adult height SDS and the midparental target height
SDS in our severely GH-deficient patients was similar to that
found in a large cohort of Caucasian GH-deficient children re-
cruited from the Kabi International Growth Study (KIGS) data-
base (31). Similar data were previously published by the
Genentech Growth Study Group (1) underlining the effective-
ness of the rhGH treatment used in our studies. From these data
also reporting final height, it can be concluded that in severe
GH-deficient subjects, the presence or absence of the GHR-d3
allele has no impact on either baseline phenotype or final height,
although a difference in response to rhGH replacement therapy
during the first years may be observed depending on the
genotype.
When comparing these findings obtained from patients with
severe IGHD with the previous studies focusing on GHR allele
genotype and response to rhGH replacement therapy, the pa-
tients, individual conditions, their related growth disorder, as
well as the rhGHdosesusedhave tobe carefully analyzed (12,14,
16). In the first report, for instance,Dos Santos et al. (12) studied
patients with either SGA or ISS. In this study, patients with nor-
mal GH secretion were treated with supraphysiological rhGH
replacement doses (12). Besides the various conditions studied,
it is alsopossible that thedifferencesbetween the studies reported
so far represent the problems of sample size. False-positive find-
ings aremore likelywith small samples sizes and for quantitative
trait loci phenotypical variations tend to be overestimated with
small sample sizes (32, 33). Only large-scale studies of well-
defined conditions or pooling data sets will help to resolve these
statistical issues. Therefore, it is worth pointing out that our
sample size is to our knowledge among the largest reported to
date.
Focusing on patients with GHD, Jorge et al. (13) pooled the
data obtained from the patients with GHR-d3/d3 and d3/fl and
compared their HV with that of patients carrying the GHR-fl/fl
genotype.The conclusiondrawn fromthedatawere thatpatients
with GHD who were homozygous for GHR-fl responded less
well to the rhGH replacement. In addition, in this study 44 GH-
deficient patients were also followed up to final height, of whom
22 carried the GHR-fl/fl and the remaining 22 either the d3/d3
or d3/fl genotype. A greater final height was achieved in patients
with one or two copies of theGHR-d3 genotypewhen compared
with the patients who were homozygous for the GHR-fl alleles
(height SDS 0.8 vs. 1.7, respectively). In contrast to our
study, in the study of Jorge et al. (13), not only subjects with
IGHD but also combined pituitary hormonal deficiencies were
analyzed, and, furthermore, HV data were only presented in
prepubertal patients during the first year of treatment. This
might at least partly explain the differences obtained. On the
contrary, Pilotta et al. (15) could not detect an influence of GHR
polymorphisms in the growth responseof54prepubertal, rhGH-
treated children. However, in comparison to our patients, these
children had a higher maximal GH increase after stimulation
tests (5  2.9 ng/ml). Unfortunately, the authors did not show
data analyzing the growth response according to the exon-3 ge-
notype present (15). In addition, although in the report by Blum
et al. (18) the GHR-d3 allele did not affect responsiveness to
conventional rhGH replacement therapy, a statistical difference
in IGF-I between the genotype groups fl/fl vs. d3/fl andd3/d3was
described. However, this finding could not be reproduced in our
study but may underline the notion that responsiveness to GH
treatment depends on the functional properties of the GHR. In
the original study by Dos Santos et al. (12), HEK293 fibroblasts
were transiently cotransfected with GHR-fl, GHR-d3, or both,
and in these experiments, the GHR-d3 induced a higher tran-
scriptional activity of the lactogenic hormone responsive ele-
ment-luciferase reporter plasmid, which is activated by GH via
binding to its GHR. In this study the dose response of GH was
studied up to the dose of 50 ng/ml, and the effect in terms of
lactogenic hormone responsive element-luciferase activation
was described as linear. This increased, and allele dose-depen-
dent responsiveness of the GHR-d3 to rhGH may explain the
better growth response during the first years of rhGH treatment
in subjects treated with the lower rhGH dose (26.5 vs. 36.5 g/
kgd) as demonstrated using the multiple linear regression mod-
els in our study.
Obviously, neither GH responsiveness nor GH sensitivity is
constant; the dose-response relationship may vary in every spe-
cific condition with/without an underlying growth disorder.
Even for a specific condition and dose-response curve, an in-
crease of rhGH dose may well itself affect GHR sensitivity, sig-
naling, and, thus, response to treatment, as is well established in
any rhGH-treated child whose response changes after the first
years on treatment (2–8). Moreover, the dose response of rhGH
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differs according to the condition that is treated. For instance,
children with GHD, Turner syndrome, SGA, or ISS respond dif-
ferently (and the rhGH dose is adapted accordingly), but a
change in GH sensitivity with treatment remains a variable.
Thus, the positive effect resulting from the GHR-d3 genotype
may well be down-regulated and/or altered when supraphysi-
ological doses of rhGH are given. This hypothesis could explain
why severe GH-deficient subjects might present a rhGH dose-
dependent GHR genotype-related effect on growth response
with an apparent plateau at around 26 g/kgd (16 IU/m2wk),
whereas this effect disappears with higher rhGH doses that lie
further up on the dose-response curve for this condition. Simi-
larly, SGAchildren treatedwithhigherdosesof rhGHshowedno
difference in growth response according to the exon-3 genotype
in contrast to SGA children treated with lower doses (12, 16).
Duration of GH treatment also seems to play a major role in
defining the sensitivity to the GHR genotype, in addition to the
etiology of the short stature and its severity.
Furthermore, as mentioned by Audi et al. (17), the GHR-d3/
GHR-fl genotypes may well contribute to the wide range of
growth in the normal population. Therefore, we studied 211
healthy Swiss control subjects of both Caucasian original and
normal stature (17). Although the prevalence of the GHR geno-
types obtained in our study differs from the Spanish controls, it
is of importance, however, to highlight the identical finding that
the prevalence of theGHR-d3/d3 andGHR-fl/fl genotypes in the
taller subgroup (height of  2 and 	 1 SDS) are respectively
higher (13.1 vs. 7.4 and 8%) and lower (39.5 vs. 50 and 48%)
when comparedwith the other two subgroups (Table 3). Similar
observations were made when the genotype frequencies of the
248 parents were studied.
In summary, in our two studies focusing on patients with
severe IGHD, we observed a GHR-d3 allele dose-dependent ef-
fect in subjects treated with rhGH during the first 2 yr, with
significantly better responses of either the GHR d3/d3 or the
GHR-d3/fl genotype, although no difference was observed at
final height. Considering all the studies focusing on IGHD (13,
15, 18, 19), it becomes clear that the final impact of the GHR
genotypes on the rhGH response is minimal. Given the impor-
tance of the response to attainment of final height, it may, nev-
ertheless, well be an additional variable having some impact on
growth and GH sensitivity, at least at the beginning of rhGH
treatment.
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